Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy
{{output}}
Immune checkpoint blockade (ICB) has significantly improved the survival for many patients with advanced malignancy. However, fewer than 50% of patients benefit from ICB, highlighting the need for more effective immunotherapy options. High-dose interleukin-2 (... ...
